6 results about "Arthritic joint" patented technology

A variety of surgical procedures may be performed on the bones of the foot, such as on one or more lesser metatarsals of the foot positioned laterally of the first metatarsal. For example, a surgical procedure may involve cutting an end of one or both of a second metatarsal and an intermediate cuneiform and / or cutting an end of one or both of a third metatarsal and a lateral cuneiform. The tarsometatarsal joints defined be one or both sets of bones may be cut to treat an arthritic joint, metatarsus adductus, and / or other clinical condition. In any case, various surgical instruments can be utilized during a procedure to help increase the accuracy and repeatability of the procedure patient-to-patient, improving overall patient outcomes. For example, one or more cut guides, compressor-distractor devices, and / or other instruments designed to accommodate the specific anatomical conditions of the procedure being performed may be utilized during procedure.

The present application relates to a kind of preparation compositions containing the preparation method of loxoprofen derivative shown in general formula (I).The composition is a kind of analgesic antipyretic for preventing and treating rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, joint deformity, gout, lumbago, neck shoulder wrist syndrome and periodontitis, cold, acute respiratory inflammation, such as postoperative inflammation of the diseases of the drug composition, its composition is characterized in that the mass percentage of loxoprofen derivative is 0.5%-5.0%w / w;Including physiologically acceptable crystal inhibitor;And at least one pH regulator.The pharmaceutical composition provided by the present application, compared with the preparation of loxoprofen derivative external preparation of the current existing technical means or the method reported in the public literature, solves the problem of active ingredient crystallization of such preparation, and achieves good effect.

A variety of surgical procedures may be performed on the bones of the foot, such as on one or more lesser metatarsals of the foot positioned laterally of the first metatarsal. For example, a surgical procedure may involve cutting an end of one or both of a second metatarsal and an intermediate cuneiform and / or cutting an end of one or both of a third metatarsal and a lateral cuneiform. The tarsometatarsal joints defined be one or both sets of bones may be cut to treat an arthritic joint, metatarsus adductus, and / or other clinical condition. In any case, various surgical instruments can be utilized during a procedure to help increase the accuracy and repeatability of the procedure patient-to-patient, improving overall patient outcomes. For example, one or more cut guides, compressor-distractor devices, and / or other instruments designed to accommodate the specific anatomical conditions of the procedure being performed may be utilized during procedure.

An object of the present invention is to provide a novel drug for suppressing progression of osteoarthritis, particularly, a novel drug for suppressing degeneration and / or loss of cartilage.SOLUTION: The present inventors have clarified that when dabigatran etexilate methanesulfonate, which is a thrombin inhibitor having an effect of inhibiting the production of fibrin from fibrinogen, is administered to a patient with knee osteoarthritis, the value indicating the total amount of cartilage matrix degradation products is decreased. That is, the present invention provides an inhibitor of cartilage degeneration in an osteoarthritic joint, the inhibitor containing a fibrin formation inhibitor as an active ingredient, and means for solving the problem.SELECTED DRAWING: None

The purpose of the present invention is to provide a novel medicine for suppressing the progression of osteoarthritis, particularly a novel medicine for suppressing degeneration and / or disappearance of cartilage. Specifically, the inventors of the present invention have found that a value indicating the total amount of a cartilage matrix degradation product decreases when dabigatran etexilate methanesulfonic acid, which is a thrombin inhibitor having an action of inhibiting the production of fibrin from fibrinogen, is administered to a patient with osteoarthritis. Specifically, in the present invention, the means for solving the problem is: an agent for suppressing degeneration of cartilage in an osteoarthritic joint, the agent containing a fibrin formation inhibitor as an active ingredient; and provision of said agent.

This invention belongs to the field of nutritional composition technology, specifically relating to a composition, composition formulation, preparation method, application, and product for improving bone health. This invention provides a composition composed of N-acetylglucosamine and 3-O-acetyl-11-keto-β-boswellic acid. The composition and formulation of this invention can promote the differentiation of chondrocyte precursor cells into mature chondrocytes, promote cartilage matrix synthesis, significantly inhibit TNF-α and MMP13 expression, and upregulate COL2A1 expression, with effects superior to single components and traditional combinations. The ingredients are natural and safe, biocompatible, and have no significant toxicity, making them suitable for people with joint noise, joint pain, osteoarthritis, and joint degeneration. Simultaneously, they can improve bone density, promote bone growth and development, and improve bone health. The preparation process is simple and low-cost, and it can be formulated into various dosage forms such as food, health products, and pharmaceuticals, offering flexible applications and combining preventative and therapeutic value.